Drug Profile
Fesomersen - Ionis Pharmaceuticals
Alternative Names: BAY-2976217; Factor XI LICA; ION-957943; IONIS-FXI-LRXLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Ionis Pharmaceuticals
- Class Amides; Amino sugars; Anticoagulants; Antisense elements; Antisense oligonucleotides; Antithrombotics; Drug conjugates
- Mechanism of Action Factor XI expression modulators; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Thrombosis
Highest Development Phases
- Phase II Thrombosis
Most Recent Events
- 04 Nov 2022 Updated efficacy data from a phase II RE-THINc ESRD presented at the American Society of Nephrology's Kidney Week (ASN-2022)
- 28 Jul 2022 Efficacy and adverse events data from phase II RE-THINC ESRD trial for Thrombosis released by Ionis
- 12 May 2022 Ionis Pharmaceuticals completes the phase II RE-THINC ESRD trial for Thrombosis in Greece, Czech Republic, Belgium, Bulgaria, Canada, Germany, Hungary, Japan, Latvia, Russia, Spain, South Korea, Taiwan, Ukraine, USA (EudraCT2019-003927-39) (NCT04534114)